Any changes to GLP-1 dosing, including maintenance or micro-dosing, should be done under medical supervision to ensure safety, effectiveness, and personalized care.
They are not independently verified by this publication, may not represent typical outcomes, and should not be interpreted as guarantees of weight loss, medication eligibility, side-effect profile, prescription approval, or health outcomes
People should not use products claiming to be retatrutide outside legitimate clinical-trial oversight
Evaluate any such sources critically and independently
Key Results: What the Data Shows Primary Endpoint: Weight Loss The 12mg retatrutide group achieved 28.3% average weight loss at 80 weeks compared to approximately 2% in the placebo group
Bottom line: a rising BMR is a sign my bodys still running strong, even with a reduced appetite